Press Releases

Press Releases

February 26, 2018
Preparing for mid-2018 approval and launch of volanesorsen for FCS in the US, EU and Canada Advancing the pipeline with four Phase 2 trials underway and data planned from two studies in 2018 Conference Call Webcast Monday, February 26 , 4:30 p.m. ET at www.akceatx.com CAMBRIDGE, Mass. , Feb.
February 15, 2018
Advisory Committee Meeting tentatively scheduled for May 10, 2018 CAMBRIDGE, Mass. , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious cardiometabolic
February 12, 2018
Webcast scheduled for Monday, February 26 at 4:30p.m. Eastern Time CAMBRIDGE, Mass. , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious
February 7, 2018
CAMBRIDGE, Mass. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), today announced it had completed enrollment of a Phase 2b clinical study of investigational drug AKCEA-APO(a)-L Rx . Akcea is conducting the study in patients with high Lp(a) and established cardiovascular
January 5, 2018
CAMBRIDGE, Mass. , Jan. 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced the
December 14, 2017
CAMBRIDGE, Mass. , Dec. 14, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced the
December 7, 2017
CAMBRIDGE, Mass. , Dec. 07, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced that
November 15, 2017
FDA Prescription Drug User Fee Act goal date set for August 30, 2018 CAMBRIDGE, Mass., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), focused on developing and commercializing drugs to treat patients with serious
November 13, 2017
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced
November 7, 2017
CAMBRIDGE, Mass. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced that